JK-05

JK-05 is an experimental antiviral drug developed by the Beijing Institute of Biotechnology and the Academy of Military Medical Sciences in China. It is designed to treat and prevent diseases caused by some filoviruses, including the Ebola virus and the Marburg virus.

Development[edit | edit source]

JK-05 was developed in response to the 2014–2016 Ebola virus epidemic in West Africa, which highlighted the need for effective treatments for filovirus diseases. The drug is named after Jiangsu Kanion Pharmaceutical, the company that manufactures it.

Mechanism of Action[edit | edit source]

JK-05 works by inhibiting the replication of the virus. It does this by blocking the action of a viral enzyme called RNA polymerase, which is necessary for the virus to reproduce.

Clinical Trials[edit | edit source]

In 2015, JK-05 was approved for emergency use in China, and it was also included in the national stockpile of emergency medicines. However, as of 2021, it has not yet been approved for general use, as it is still undergoing clinical trials.

See Also[edit | edit source]

JK-05 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.